Entera Bio Advances Pipeline with Streamlined EB613 Protocol and Expanded OPKO Collaborations
Event summary
- Entera Bio submitted a streamlined Phase 3 protocol for EB613 to the FDA, aiming for topline results in late 2028, a year earlier than previously expected.
- The company selected final variants for EB612 and initiated pre-IND activities, with an IND filing planned for late 2026 in partnership with OPKO.
- EB618 completed PK/PD validation, with plans to file an IND based on OPKO's Phase 1 data for the injectable formulation.
- Entera Bio reported a net loss of $11.4 million for 2025, with cash reserves expected to support operations through mid-Q3 2026.
The big picture
Entera Bio's progress in streamlining the Phase 3 protocol for EB613 and expanding its collaborations with OPKO positions it as a key player in the oral peptide therapy space. The company's focus on capital efficiency and regulatory alignment could enhance its competitive edge in treating osteoporosis, hypoparathyroidism, and metabolic syndromes. However, sustaining financial health while advancing multiple pipelines remains a critical challenge.
What we're watching
- Regulatory Alignment
- Whether the FDA's feedback on the streamlined Phase 3 protocol for EB613 will accelerate approval timelines and reduce development costs.
- Pipeline Execution
- The pace at which Entera Bio can advance its multiple programs, particularly EB612 and EB618, while maintaining capital efficiency.
- Financial Sustainability
- How Entera Bio will manage its cash reserves to support operations through 2026 and beyond, given the increased R&D and administrative expenses.
Related topics